IDEAYA Biosciences said it enrolled the first patient in its Phase 1 dose escalation/expansion trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 antibody-drug conjugate. The trial will evaluate IDE034’s safety, tolerability and pharmacokinetics as monotherapy, and the company also plans to test combinations with DNA damage response agents including its proprietary PARG inhibitor IDE161. IDEAYA estimated B7H3 and PTK7 are co-expressed in about 30% to 40% of certain solid tumors, including lung, breast, ovarian and colorectal cancers. Dosing of the first patient triggered a $5 million milestone payment from IDEAYA to Biocytogen under the companies’ option and license agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602250600PR_NEWS_USPR_____SF95183) on February 25, 2026, and is solely responsible for the information contained therein.